Aim COVID-19 has brought unprecedented challenges to the healthcare system. The rapid spread of the virus, laboratory burn-out, exhausted staff, diagnostic uncertainty and lack of guidelines cumulatively disrupted hospital antimicrobial stewardship (AMS) programs. This scoping review evaluated how the COVID-19 pandemic has impacted the implementation of AMS, particularly within the context of clinical audits.

Methods An initial trend analysis was performed using a database search from 2000 to 2022. This review was developed following PRISMA-Scr guidelines. Databases such as Medline, Embase, Cochrane Library and CINAHL were searched using Medical Subject Headings and free text for ‘Children’, ‘antimicrobial stewardship’ and ‘COVID-19’. Primary studies that reported data on antimicrobial use among hospitalised children during COVID-19 from December 2019 to December 2022 were considered.

Results Paediatric AMS-related research output changed annually by −4.94% in 2022 compared to 14.44% in 2019. Of 677 articles, 15 were included, with 3 added through snowballing technique. All the studies were observational and from countries of all income levels. A quantitative measure of antibiotic use was the commonly assessed sub-category of AMS, while three studies performed the audit for a reason for antibiotic use, microbiological cultures, and surgical prophylaxis. Most studies reported antimicrobial use as prevalence, while two reported the days of therapy, and two used the AWaRe classification and the antibiotic spectrum index (ASI).

Conclusions Paediatric AMS activities were disrupted during the COVID-19 pandemic. A basic quantitative measure of antibiotic use was the only measure of assessment, with other AMS components unreported. A robust paediatric-focused AMS resilient to future pandemics and evidence-informed stewardship approach is needed.